Anti-Progesterone in Breast Cancer Chemoprevention

Tech ID: 18780 / UC Case 2006-560-0

Background

BRCA1 is a breast cancer susceptibility gene. According to estimates of lifetime risk, 36 to 85 percent of women with an altered BRCA1 or BRCA2 gene will develop breast cancer.

Technology Description

Treatment with anti-progesterone, mifepristone, prevents tumorigenesis in mice carrying mutated Brca1/p53 alleles.

Anti-progesterone pellet containing 30mg/60 days constant release mifepristone (RU486), or placebo pellet was implanted into twelve 3- and two 4- month-old mice. Mice were monitored weekly for tumor formation. All control mice or placebo pellet treated mice developed palpable tumors. In the RU486 treated group no palpable tumors were detected.

The invention is published in Science 1 December 2006 314: 1467-1470

Applications

Treatment of BRCA1 mediated breast cancer

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,517,240 12/13/2016 2006-560
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2009 - 2016, The Regents of the University of California
Terms of use | Privacy Notice